DIR fees have risen 45,000% and are crippling pharmacists and pharmacies from being able to do business especially in the specialty arena. Community pharmacists that specialize and serve the HIV community are an integral part of the patients healthcare team and effect positive outcomes and lower healthcare costs. Pharmacies are having hundreds of thousands of dollars clawed back for DIR fees months after the drugs have been dispensed to patients and paid for by pharmacies. The patient care provided and adherence rates of the HIV patients serviced are way above other and yet this unregulated criminal behavior of PBMs continues. If the government truly wants to lower healthcare costs STOP DIR fees and STOP this egregious behavior of PBMs. Pharmacists are only seeking fair reimbursement for their extraordinary work and patient care. Support bipartisan disappointment by contacting your representative DIR fees have risen 45,000% and are crippling pharmacists and pharmacies from being able to do business especially in the specialty arena. Community pharmacists that specialize and serve the HIV community are an integral part of the patients healthcare team and effect positive outcomes and lower healthcare costs. One of my pharmacy clients lost over $200,000 clawed back for DIR fees last year and is on track for even more this year. The patient care provided and adherence rates of the HIV patients serviced are way above other and yet this unregulated criminal behavior of PBMs continues. If the government truly wants to lower healthcare costs STOP DIR fees and STOP this egregious behavior of PBMs.

Pharmacists are only seeking fair reimbursement for their extraordinary work and patient care.

Support bipartisan expression of disappointment to President Trump on Pharmacy DIR fees today . Contact your Representative and urge them to sign onto a bipartisan letter to President Trump being led by community pharmacy champions Reps.Peter Welch (D-Vt.), Vicente Gonzalez (D-Texas), Buddy Carter (R-Ga.) and Morgan Griffith (R-Va). The letter echoes a similar Senate letter led by Sens. Shelley Moore Capito (R-W.Va.) and Jon Tester (D-Mont.) and expresses disappointment with the Trump administration’s failure to act on the pharmacy DIR issue in the recently finalized drug pricing rule. Send a letter to your US Representative HERE

#PBM #DIRfees #PharmacyBusiness #Reimbursement #HIVPharmacy #UbuntuPharmacistCareProgram